MedCap (MCAP) Q4 14/15 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 14/15 earnings summary
13 Nov, 2026Executive summary
FY2014/15 revenue grew to SEK 852.8m from SEK 826.1m, while net profit fell to SEK 9.5m from SEK 26.3m amid weaker profitability at Abilia and Unimedic and restructuring activity.
Positive operating cash flow, a SEK 50m directed share issue and lower borrowings strengthened the financial position; focus remained on developing existing holdings and pursuing disciplined add-on acquisitions.
Financial highlights
Revenue was SEK 852.754m versus SEK 826.086m; operating profit was SEK 10.940m versus SEK 30.888m; profit after tax was SEK 9.458m versus SEK 26.258m.
Adjusted EBITDA was SEK 31.034m versus SEK 55.412m; adjusted EBITDA excludes depreciation and amortization and segment management fees as described in segment reporting.
Operating cash flow was SEK 2.258m versus SEK 0.865m; year-end cash was SEK 75.341m versus SEK 21.222m, and borrowings were SEK 141.536m versus SEK 191.630m.
A SEK 50m directed share issue was completed in May 2014; the year-end share price was SEK 2.76 versus SEK 4.25, with FY share performance of -33% versus +9% for the First North All-Share index.
Outlook and guidance
Specialty Pharma was expected to remain the primary growth engine, supported by further proprietary product registrations and Nordic licensing agreements.
Unimedic planned continued CDMO efficiency measures and a streamlined Pharma Trading operation; new CDMO products were expected to begin selling in FY2015/16.
Abilia aimed to build on UK growth, integrate operations and pursue international distribution, while Quickels planned new product launches and expansion into additional markets.
Acquisition capacity was estimated at just over SEK 50m in equity, or approximately SEK 100m including expected debt financing; investment discipline remained a priority despite high acquisition prices.
Latest events from MedCap
- Q3 sales rose 13%, adjusted EBITA 30%, with low leverage supporting acquisitions.MCAP
Q3 2026 - FY sales grew 43% and adjusted EBITDA 45%, with growth across all business areas.MCAP
Q4 2023 - Q2 2026 net sales up 16% and EBITA up 28%, with strong margins and active acquisitions.MCAP
Q2 2026 - Adjusted EBITA rose 30% on 13% higher sales, with strong growth across all segments.MCAP
Q1 2026 - Q4 2025 delivered 25% sales growth, 68% EBITA growth, and robust margins across all segments.MCAP
Q4 2025 - Strong growth in life science through buy & build, with 19% sales and 29% EBITA CAGR.MCAP
Company presentation - Strong revenue growth and strategic acquisitions drive expansion in life science markets.MCAP
AGM 2025 presentation - Achieved SEK 1,807 million revenue in 2024 with a 23% EBITA CAGR, driven by acquisitions.MCAP
Company presentation - Life science group achieves robust growth via acquisitions and innovation in core business areas.MCAP
SEB Nordic Seminar presentation